All entries for: ADC Therapeutics SA-Switzerland

March 10, 2026

ADC Therapeutics SA-Switzerland

Neutral Outlook

Switzerland
51-200 employees

Thus, while it is unclear how some provisions of the IRA will be implemented, we are liable for Part B inflation rebates for ZYNLONTA under the IRA, which has and will continue to negatively impact our gross-to-net adjustment for ZYNLONTA sales.

Disease Area: Hematology, Oncology
Drug Type: Biologic
Scroll to Top